BRPI1010987A2 - composições farmacêuticas de liberação controlada. - Google Patents

composições farmacêuticas de liberação controlada.

Info

Publication number
BRPI1010987A2
BRPI1010987A2 BRPI1010987-0A BRPI1010987A BRPI1010987A2 BR PI1010987 A2 BRPI1010987 A2 BR PI1010987A2 BR PI1010987 A BRPI1010987 A BR PI1010987A BR PI1010987 A2 BRPI1010987 A2 BR PI1010987A2
Authority
BR
Brazil
Prior art keywords
controlled release
pharmaceutical compositions
release pharmaceutical
active ingredient
pharmaceutically active
Prior art date
Application number
BRPI1010987-0A
Other languages
English (en)
Inventor
Kinter Kevin
Ramsey Peter
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of BRPI1010987A2 publication Critical patent/BRPI1010987A2/pt
Publication of BRPI1010987B1 publication Critical patent/BRPI1010987B1/pt
Publication of BRPI1010987B8 publication Critical patent/BRPI1010987B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Eyeglasses (AREA)

Abstract

composições de ligação de droga de explosão uma composição de dosagem sólida compreendendo pelo menos um ingrediente farmaceuticamente ativo e pelo menos um agente de liberação controlada e método de fabricação a referida composição é descrita. o perfil de explosão de pelo menos um ingrediente farmaceuticamente ativo na composição é regulada pela viscosidade aparente do agente de liberação controlada e onde pelo menos um ingrediente farmaceuticamente ativo é processado por granulação úmida .
BRPI1010987A 2009-05-13 2010-05-13 composições de dosagem sólida de liberação controlada contendo ibuprofeno BRPI1010987B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17794309P 2009-05-13 2009-05-13
US61/177.943 2009-05-13
PCT/US2010/034660 WO2010132635A1 (en) 2009-05-13 2010-05-13 Burst drug release compositions

Publications (3)

Publication Number Publication Date
BRPI1010987A2 true BRPI1010987A2 (pt) 2019-04-02
BRPI1010987B1 BRPI1010987B1 (pt) 2020-06-02
BRPI1010987B8 BRPI1010987B8 (pt) 2021-05-25

Family

ID=42647324

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010987A BRPI1010987B8 (pt) 2009-05-13 2010-05-13 composições de dosagem sólida de liberação controlada contendo ibuprofeno

Country Status (23)

Country Link
US (2) US20100311839A1 (pt)
EP (2) EP3459530B1 (pt)
JP (2) JP5740396B2 (pt)
KR (1) KR101471240B1 (pt)
CN (2) CN107028909A (pt)
AR (1) AR076907A1 (pt)
AU (1) AU2010248979A1 (pt)
BR (1) BRPI1010987B8 (pt)
CA (1) CA2761795C (pt)
CO (1) CO6390100A2 (pt)
ES (1) ES2707275T3 (pt)
HU (2) HUE053202T2 (pt)
IL (1) IL216186B (pt)
MX (1) MX336065B (pt)
NZ (1) NZ596275A (pt)
PL (1) PL2429501T3 (pt)
PT (1) PT2429501T (pt)
RU (2) RU2541807C2 (pt)
SG (2) SG10201402285XA (pt)
TR (1) TR201900220T4 (pt)
TW (1) TWI478733B (pt)
WO (1) WO2010132635A1 (pt)
ZA (1) ZA201109084B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP3448358B1 (de) * 2016-04-26 2021-09-08 LTS Lohmann Therapie-Systeme AG Filmförmige darreichungsform zur transmukosalen verabreichung von peptid-antidiabetika
CN117017932B (zh) * 2023-08-24 2024-05-24 浙江和沐康医药科技有限公司 一种舒林酸片组合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
JPH01319416A (ja) * 1988-06-21 1989-12-25 Dai Ichi Kogyo Seiyaku Co Ltd 放出制御可能な錠剤結合剤
JPH05255125A (ja) * 1992-02-29 1993-10-05 Upjohn Co:The 徐放性製剤およびその製法
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
US20040101494A1 (en) * 2002-11-26 2004-05-27 Scott Douglas Craig Chewable solid unit dosage forms and methods for delivery of active agents into occlusal surfaces of teeth
US20040265373A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US20060068009A1 (en) * 2004-09-30 2006-03-30 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20070077297A1 (en) * 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet

Also Published As

Publication number Publication date
TR201900220T4 (tr) 2019-02-21
CA2761795A1 (en) 2010-11-18
HUE042857T2 (hu) 2019-07-29
CO6390100A2 (es) 2012-02-29
EP3459530A1 (en) 2019-03-27
AU2010248979A1 (en) 2011-11-24
IL216186A0 (en) 2012-01-31
KR101471240B1 (ko) 2014-12-09
TWI478733B (zh) 2015-04-01
ZA201109084B (en) 2012-08-29
HUE053202T2 (hu) 2021-06-28
NZ596275A (en) 2014-01-31
PT2429501T (pt) 2019-01-30
US20130116327A1 (en) 2013-05-09
RU2014146936A (ru) 2016-06-10
MX336065B (es) 2016-01-06
TW201105367A (en) 2011-02-16
SG175892A1 (en) 2011-12-29
CA2761795C (en) 2017-02-21
PL2429501T3 (pl) 2019-06-28
US20100311839A1 (en) 2010-12-09
KR20120012485A (ko) 2012-02-10
BRPI1010987B8 (pt) 2021-05-25
RU2014146936A3 (pt) 2018-06-04
IL216186B (en) 2019-10-31
ES2707275T3 (es) 2019-04-03
WO2010132635A1 (en) 2010-11-18
CN102458375A (zh) 2012-05-16
JP5740396B2 (ja) 2015-06-24
MX2011012045A (es) 2011-12-12
BRPI1010987B1 (pt) 2020-06-02
CN107028909A (zh) 2017-08-11
EP2429501B1 (en) 2018-11-21
EP3459530B1 (en) 2020-09-23
RU2011145436A (ru) 2013-06-20
SG10201402285XA (en) 2014-08-28
EP2429501A1 (en) 2012-03-21
AR076907A1 (es) 2011-07-20
JP2015155452A (ja) 2015-08-27
JP2012526841A (ja) 2012-11-01
RU2541807C2 (ru) 2015-02-20

Similar Documents

Publication Publication Date Title
CR11285A (es) Composicion farmaceutica que contiene un antagonista del canal de calcio de tipo dihipropiridina y metodo para la prepacion de la misma
UA103347C2 (ru) Фармацевтическая препаративная форма, которая содержит нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
BR112013009153A2 (pt) formulação de ligante de fosfato para dosagem única.
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
BR112015011430A2 (pt) composição para liberação imediata e prolongada
UY30535A1 (es) Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
PL3003285T3 (pl) Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
FR2915683B1 (fr) Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
TR201821157T4 (tr) İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m.
BR112012021445B8 (pt) formulação farmacêutica ou neutracêutica, e uso de um agente promotor de biodisponibilidade
AR070392A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de eleboracion
BRPI1010987A2 (pt) composições farmacêuticas de liberação controlada.
CL2008000931A1 (es) Particula solidad de vacuna oral entrecruzada que contiene un ingrediente farmaceuticamente activo un bioadhesivo, un oligasacarido, una mezcla mediadiora que comprende un emulsionante y uno o mas monosacaridos y/o disacaridos; metodo para su preparacion; uso de la particula solidad de vacuna oral.
PE20160245A1 (es) Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion
HK1218862A1 (zh) 包含异烟肼颗粒和利福喷汀颗粒的呈包衣片剂形式的抗结核病的稳定的药物组合物及其制备方法
BRPI0719467A2 (pt) " usos de pelo menos um composto para a fabricação de uma composição farmacêutica destinada ao tratamento de afecções dermatológicas"
MX2019004414A (es) Un nuevo metodo para producir hemihidrato de sulfato de calcio con propiedades unicas.
IL281217A (en) Pharmaceutical preparation for controlled release of weak acid drugs and its uses
PE20090316A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente antioxidante para el tratamiento de infecciones urinarias

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/06/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/05/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: WYETH LLC (US)

B25A Requested transfer of rights approved

Owner name: PF CONSUMER HEALTHCARE 1 LLC (US)